Zhejiang Doer Biologics Concludes Patient Recruitment in P-Ib/IIa Study of DR10624 Among Obese Individuals
Shots:
- Zhejiang Doer Biologics has concluded the patient recruitment in P-Ib/IIa trial, the results of which are expected in early 2025
- The P-Ib/IIa trial is to determine the safety, tolerability & PK/PD of DR10624 (SC) vs PBO in obese adults (BMI: 30-45kg/m^2) having modest hypertriglyceridemia (fasting triglyceride: ≥150mg/dL & <500 mg/dL at screening) for 12wks. Trial will also assess the drug’s effect on serum lipids, liver fat & body weight
- DR10624, developed using Doer Bio's MultipleBody platform, is a long-acting tri-specific agonist targeting FGF21R, GLP-1R & GCGR that showed its potential to reduce body weight, normalize blood lipids & improve liver function in preclinical studies
Ref: PR Newswire | Image: Zhejiang Doer Biologics
Related News:- Neurobo Pharmaceuticals Reports First Patient Dosing in P-I Study of DA-1726 to Treat Obesity
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
